SAN DIEGO - Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biotech company currently valued at $171 million, has shared promising clinical data from its studies of azenosertib, a small ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2Planned workforce ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which ...

A study by DKFZ researchers shows that inhibiting the enzyme aldolase A in glycolysis traps energy in liver cancer cells, ...

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics ...

Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung Cancer Oct. 31, 2024 — A new study has found a surprising link between high levels of methylmalonic acid and the weakening of ...